The US research-based pharma industry is continuing to call for broad reforms to ensure the sustainability of Japan’s healthcare ecosystem, which it sees as essential to rebuilding the country’s attractiveness as a location for innovation and new drug development.
As to what the most appropriate forum for such a dialog would be, Pharmaceutical Research and Manufacturers of America (PhRMA)...